Stockscreener 앱 받기
21.41
0.47%
0.10
전일 마감가:
$21.31
열려 있는:
$21.38
하루 거래량:
22,026
Relative Volume:
0.32
시가총액:
$920.63M
수익:
-
순이익/손실:
$-75.28M
주가수익비율:
-10.73
EPS:
-1.9957
순현금흐름:
$-57.45M
1주 성능:
-0.83%
1개월 성능:
-5.43%
6개월 성능:
+79.24%
1년 성능:
+70.73%
1일 변동 폭
$21.38
$21.55
1주일 범위
$20.95
$21.86
52주 변동 폭
$10.55
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
OCS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
21.41 | 920.63M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
(OCS) On The My Stocks Page - Stock Traders Daily
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 68.6% in January - MarketBeat
Oculis (NASDAQ:OCS) Shares Down 7.2%Should You Sell? - MarketBeat
Oculis Holding AG Prices $100 Million Oversubscribed Share Offering - TipRanks
Oculis Holding Prices Offering of 5 Million Shares -February 14, 2025 at 04:36 am EST - Marketscreener.com
Biopharmaceutical Company Oculis Seeks $100 Million from Share Sale -February 14, 2025 at 12:56 am EST - Marketscreener.com
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares - The Manila Times
Major Funding Breakthrough: Oculis Secures $100M for Revolutionary Eye Treatment Development - StockTitan
Oculis Raises Massive $100M War Chest: Major Pipeline Expansion for Revolutionary Eye Treatment - StockTitan
Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum - GlobeNewswire Inc.
Institutions along with retail investors who hold considerable shares inOculis Holding AG (NASDAQ:OCS) come under pressure; lose 8.9% of holdings value - Simply Wall St
(OCS) Trading Report - Stock Traders Daily
abrdn plc Buys 188,871 Shares of Oculis Holding AG (NASDAQ:OCS) - MarketBeat
Oculis (NASDAQ:OCS) Trading Down 0.2%Time to Sell? - MarketBeat
Insider Alert: Oculis Leadership Team Hits Major Share Vesting Milestone - StockTitan
Oculis (NASDAQ:OCS) Shares Down 0.2% – Time to Sell? - Defense World
Oculis updates share capital for its existing at-the-market offering program - The Manila Times
Oculis Secures Financial Flexibility: Strategic $100M ATM Program Backed by 2.5M Fresh Shares - StockTitan
Here's Why Momentum in Oculis Holding AG (OCS) Should Keep going - MSN
Trend Tracker for (OCS) - Stock Traders Daily
Oculis Announces Significant Voting Rights Changes Following Íslandsbanki Activity - StockTitan
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care (NASDAQ:OCS) - Seeking Alpha
Oculis Announces Major Voting Rights Changes Involving Íslandsbanki in Switzerland - StockTitan
(OCS) Proactive Strategies - Stock Traders Daily
Here's What Could Help Oculis Holding AG (OCS) Maintain Its Recent Price Strength - MSN
Oculis (NASDAQ:OCS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy - MENAFN.COM
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Chardan Capital Reiterates Buy Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's Why - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis' (OCS) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Oculis reiterates shares target, buy rating post-trial - Investing.com
Stifel maintains Oculis stock Buy rating, $35 target post-study - Investing.com India
Oculis Trial Shows Potential for Optical Neuroprotective Therapy - Yahoo Finance
Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis - TipRanks
Stifel maintains Oculis stock Buy rating, $35 target post-study By Investing.com - Investing.com South Africa
Oculis' (OCS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Oculis presents 'groundbreaking' data in optic neuritis with OCS-05 - BioWorld Online
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):